You are here

• Home
• About AstraZeneca US
• Newsroom

• Product news

The following shows headlines of all product-related news articles published within 12-months, starting from most recent.

• Pages
• Previous
• 1
• 2
• 3
• Next

• • Mar 11, 2010
  • AstraZeneca comments on FDA Joint Advisory Committee meeting on post-marketing safety studies for the use of LABAs in asthma  
• • Mar 9, 2010
  • Bristol-Myers Squibb and AstraZeneca announce the commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial (SAVOR-TIMI 53)  
• • Feb 8, 2010
  • US FDA approves new indication for CRESTOR® (rosuvastatin calcium)  
• • Dec 15, 2009
  • Favorable vote from FDA Advisory Committee on benefit/risk of CRESTOR® (rosuvastatin calcium) in JUPITER study  
• • Dec 11, 2009
  • Advisory Committee briefing materials for CRESTOR® sNDA available on US FDA web site  
• • Dec 10, 2009
  • Phase III CONFIRM study shows FASLODEX® (fulvestrant) Injection 500 mg may delay time of disease progression over 250-mg dose in postmenopausal women with hormone receptor-positive advanced breast cancer  
• • Dec 4, 2009
  • US FDA approves SEROQUEL for the pediatric treatment of schizophrenia and bipolar mania  
• • Nov 17, 2009
  • CRESTOR® reduced risk of cardiovascular events in women by nearly half in new analysis of JUPITER study  
• • Nov 9, 2009
  • New post-hoc, pooled analysis shows SYMBICORT® improved airflow obstruction in patients with COPD  
• • Oct 16, 2009
  • U.S. Food and Drug Administration approves CRESTOR® for use in pediatric patients with heterozygous familial hypercholesterolemia  

• Pages
• Previous
• 1
• 2
• 3
• Next

Page tools

• Print
• Bookmark this page
• Subscribe to RSS news feed